Scalper1 News
Merck agreed to sell its consumer business to German giant Bayer for $14.2 billion Tuesday, continuing big pharma’s recent flurry of big deals. Merck’s stock fell 2.6% to close at 57.11, while Bayer’s stock dipped 0.8% to 137.88. The two companies also announced a global collaboration to develop and market Bayer’s (BAYRY) line of treatments for pulmonary hypertension. The first of these, Adempas, was approved in the U.S. in October. Merck will pay Scalper1 News
Scalper1 News